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ABSTRACT
It is now well established that acetylsalicylic acid — one of the most widely prescribed drugs today — has brought a new 
era in maternal-fetal medicine. The History of medicine mentions several antecedents. Extracts made from willow contained 
in clay tablets are reported in both ancient Sumer and Egypt. In 400 BC, Hippocrates referred to the use of salicylic tea 
to reduce fevers. In the 1950s, acetylsalicylic acid entered the Guinness Book of Records as the highest selling painkiller. 
There is little doubt that acetylsalicylic acid — one of the first drugs to enter common usage — remains one of the most 
researched drugs in the world.
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INTRODUCTION
Hypertension complicates approximately 10% of all 
pregnancies, including 2–3% of preeclamptic gestations [1]. 
Preeclampsia (PE) remains a major concern for all obstetri-
cians around the world. It is a systemic vascular disorder, 
characterized by the onset of hypertension in a previously 
normotensive patient, and is accompanied by proteinu-
ria or multiple organ failure, developing after 20 weeks of 
gestation.
Contributing causes of PE development include: abnor-
mal transformation of the spiral arteries during placenta-
tion, impaired placental perfusion, hypoxia, and ischemia 
(which results in an excess of angiogenic factors, i.e. soluble 
fms-like tyrosine kinase [sFlt-1] and soluble endoglin [sEng], 
which lead to increased vascular permeability and blood 
vessel contraction, as well as the activation of a coagulation 
cascade). Analysis of the blood flow in maternal arteries is 
a good detector of pregnant women at a high-risk of PE. 
Blood flow resistance in maternal arteries decreases in the 
course of an uncomplicated pregnancy and significantly 
increases in patients with a high risk of PE [2]. As a result, 
hypertension, proteinuria, and other clinical manifestations 
have been observed [3]. Acetylsalicylic acid appeared at the 
end of the 19th century as a synthetic analgesic agent with 
improved gastric tolerability vs. naturally occurring salicy-
lates. It was marketed as aspirin in 1899 and turned out to 
be a good antiplatelet agent. Not so long ago, it was also 
described as a safe and effective drug to reduce the rate of 
PE in high-risk pregnant women [3, 4]. 
ACETYLSALICYLIC ACID IN FETAL MEDICINE
Following reports on aspirin as an effective anti-inflam-
matory and anti-platelet agent, observational studies on 
pregnant women were performed. Crandon and Isherwood 
(1979) showed that a regular intake of aspirin was linked to 
a lower incidence of PE. Beaufils et al. (1985) suggested that 
antiplatelet therapy — given early in pregnancy to high-risk 
patients — may protect against PE and fetal growth restric-
tion [5]. PE is still a common cause of both maternal and 
fetal complications. The only effective method of treatment 
— delivery — results in prematurity and the subsequent 
complications. Therefore, preventive measures are of the 
utmost importance to lower the risk of PE. The pathogenesis 
is complex and all interventions so far have not generated 
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the expected results in the general population of pregnant 
women. Low doses (60–150 mg) of acetylsalicylic acid in 
high-risk patients seem to be the only effective method. It 
has been observed that PE is associated with elevated levels 
of platelet thromboxane, which led to a number of stud-
ies on the role of acetylsalicylic acid in disease prevention 
among high-risk women. In contrast to high doses, low dos-
es (60–150 mg) of acetylsalicylic acid reduce thromboxane 
production, while preserving the synthesis of prostacyclin in 
the vascular walls [6]. In 1982, the inhibition of prostacyclin 
formation was alleged to be a facilitator of both thrombosis 
and obstetrical problems in patients with lupus anticoagu-
lant. This opened a new chapter in maternal-fetal medicine 
— a prophylaxis of conditions named thrombophilia. Aspirin 
in low doses is the single most cost-effective medicine for 
the prevention of the secondary events of thrombosis [7]. 
ASPIRIN — A “NEW” MECHANISM OF ACTION
Since acetylsalicylic acid is long established as an anal-
gesic, antipyretic, and antiplatelet drug, alternative modes 
of action have received insufficient recognition, up until 
now. Interestingly, aspirin induces the production of pro-re-
solving lipid-derived mediators – similar to endogenous 
mediators. These biochemical agents are built from ara-
chidonic acid (AA), omega-3 polyunsaturated fatty acids 
(PUFAs), and aspirin-triggered lipoxins (ATLs), binding to 
a dedicated receptor (ALXR) [7]. ATLs act as antioxidant and 
immunomodulators, promoting inflammation resolution, 
and inhibiting blood vessel proliferation [7, 8]. Increases of 
both ALXR expression in the human decidua, and of serum 
lipoxin A4 level during the first trimester of pregnancy, may 
be a starting point in the understanding of aspirin effective-
ness in PE or placental pathologies [9]. It is hypothesized 
that early (before 34 + 0 weeks, around 20% of cases) and 
late (after 34 + 0 weeks, around 80% of cases) onset PE have 
different etiologies, but a common place of origin — the 
placenta [10]. Considering the high prevalence of PE, and 
its serious complications both for mothers and newborns, 
prediction and prophylaxis represent twin-challenges in 
modern obstetrics.
A “LOW-DOSE” ASPIRIN 
— HOW MUCH IS ENOUGH?
International associations recommend 60–80 mg of 
aspirin for women at high risk of developing PE. In 2014, 
the United States Preventive Services Task Force (USPTF) 
published a meta-analysis employing doses of between 
49–150 mg, and there was no evidence of a dose-response 
relationship [11]. A dosage of at least 75 mg per day 
had a greater benefit in reducing the risk of preeclamp-
sia than a dosage of less than 75 mg per day (risk ratio 
[RR], 0.58 [95% confidence interval (CI), 0.36–0.95]; and 
RR, 0.85 [95% CI, 0.68–1.05] respectively). An 81 mg dose 
emerged because of its availability in the United States 
and being within a low-dose range (75–150 mg). Guidance 
issued to patients — for the use of different low-doses of 
aspirin to prevent PE — is summarized in Table 1 (modified 
from Jackson&Gregg, 2017) [12]. Aspirin resistance research 
has also increased notably in recent years with pregnant 
women [13, 14].  Recently, reports supporting doses reach-
ing the upper values of the “low-dose” range have emerged, 
and a meta-analysis of forty-five RCTs — including a total 
of 20,909 pregnant women showing a dose-dependent 
benefit to therapy — was published [15]. Higher dosages 
initiated < 16 weeks of gestation and were associated with 
a greater reduction of all three outcomes (PE, severe PE, 
and fatal growth restriction). Since meta-analyses are the 
most powerful tool in implementing recommendations, 
the authors take up the position of prescribing 150 mg of 
aspirin per day. 
CIRCADIAN TIMING OF ASPIRIN
Chronology in aspirin administration was once an issue. 
A double-blind placebo-controlled trial on pregnant women 
at high risk of PE, and a prospective trial on patients with un-
treated mild hypertension, both concluded that a low-dose 
of acetylsalicylic acid lowers blood pressure when admin-
istered at bedtime and not on waking [16, 17]. In another 
trial, the authors conducted a prospective, randomized, 
double-blind, placebo-controlled, chronotherapy trial on 
350 high-risk pregnant women 13.5 ± 1.4 weeks of gesta-
tion at the time of recruitment [18], finding that a low-dose 
aspirin ingested at bedtime, but not on waking, significantly 
regulates ambulatory blood pressure and reduces the in-
cidence of PE, gestational hypertension, preterm delivery, 
and IUGR. Interestingly, the described effect was expressed 
to a larger extent in women, patients with elevated fasting 
glucose, and a high glomerular filtration rate [19].
VALUABLE NOT ONLY IN PREECLAMPSIA
Fetal growth restriction (FGR) and PE are thought to 
be different syndromes of the same disorder: placental 
dysfunction. Ness and Sibai hypothesized that endothelial 
dysfunction precedes abnormal placentation, and that both 
are cornerstones of PE and FGR pregnancies. They suggest 
that the particular clinical manifestation is determined by 
certain metabolic disturbances [20]. 
A low aspirin dosage (50–150 mg/day) — started 
16 weeks before gestation in high-risk woman — was as-
sociated with a significant reduction in perinatal death and 
FGR, with a mean birth weight increment of 209 g (95% 
CI: 100–319) [21]. A meta-analysis of 17 randomized tri-
als showed a 50% reduction of FGR risk (RR: 0.47; 95% CI: 
0.36–0.62, P < .01) using 60–150 mg of aspirin/day [22].
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THE NEW ERA OF PE PROPHYLAXIS 
— THE ASPRE STUDY
Although many studies have demonstrated the bene-
fits of aspirin administration during pregnancy, the first 
randomized controlled trials failed to prove any remarkable 
advantages of such prophylaxis [23]. For this reason, a large, 
multicentre randomized, placebo-controlled European Trial 
(ASPRE) was conducted by Professor Kypros Nicolaides of 
King’s College Hospital in London. The results have recently 
been published in The New England Journal of Medicine [24]. 
A group of 1776 women in singleton pregnancies, at a high 
risk of PE, were randomly assigned to receive either aspirin 
at a dose of 150 mg or placebo, starting from 11 to 14 weeks 
of gestation until 36 weeks of gestation. The study was de-
signed to answer the question regarding aspirin influence 
on PE, which arose from ambiguous meta-analyses. Firstly, 
the authors took an alternative approach to their screening 
method, the effectiveness of which was validated in a study 
involving approximately 60,000 women. The combined mul-
timarker screening is a combination of a priori risk together 
with medical information acquired at 11–13 weeks of gesta-
tion, employing Bayes’ theorem. This detects 76% of preterm 
cases and 38% of term PE [25]. The trial was distinguished 
from other aspirin-based studies by the high accuracy across 
the range of high-risk patients. The variables calculated 
in the algorithm were: age, height, weight, racial origin, 
chronic hypertension, systemic lupus erythematosus or 
antiphospholipid syndrome, method of conception, parity 
in regard to the history of PE and intergestational interval, 
family history of PE, diabetes mellitus type 1 or 2, cigarette 
smoking, mean arterial pressure, uterine artery pulsatility 
index, pregnancy associated plasma protein-A (PAPP-A), and 
Table 1. Selected organization guidance on patients who are appropriate candidates for the use of different low-doses of aspirin to prevent 
preeclampsia (modified from Jackson&Gregg 2017 [12] )
USPTF 60–150 mg [11] ACOG 60–80 mg [28] NICE 75 mg [29] WHO 75 mg [30]
High risk > 1
History of PE x x x x
Multifetal gestation* x x — x
Chronic hypertension x x x x
Diabetes type 1 or 2 x x x x
Renal disease x x x x
Autoimmune disease x x x x
Moderate risk > 1**
Nulliparous x — x —
Age > 40 years — — x —
> 10 years IPI x — x —
First degree relative x — x —
BMI >35 kg/m2 — — x —
Multifetal gestation — — x —
Low SES x — — —
Age > 35 years x — — —
BMI > 30 kg/m2 x — — —
Patient born LBW x — — —
Prior APO x — — —
ACOG — American College of Obstetricians and Gynecologists; APO — adverse pregnancy outcome (not specifically defined); BMI — body mass index; 
IPI, — interpregnancy interval; LBW — low birth weight; NICE — National Institute for Health and Care Excellence (United Kingdom); PE — physical education; 
SES — socioeconomic status (not specifically defined); USPTF — U.S. Preventive Services Task Force; WHO — World Health Organization
* Multifetal gestation is not a high-risk factor but is a moderate-risk factor in the NICE guidance 
** Moderate-risk factors are those with less than 8% risk. NICE proposes 2 or more for aspirin prophylaxis
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placental growth factor (PIGF). Moreover, the authors looked 
for preterm rather than total PE. A threshold for “high-risk” 
pregnancy was established at > 1:100 and delivery with PE 
before 37 weeks of gestation was measured as a primary out-
come. The participants were randomly assigned to aspirin or 
placebo groups, in a 1:1 ratio. PE before 37 weeks’ gestation 
was diagnosed in 13 of 798 (1.6%) patients in the aspirin 
group and 35 of 822 (4.3%) in the placebo group (adjusted 
odds ratio in the aspirin group — 0.38; 95% CI; 0.2 to 0.74; 
P = 0.004). The trial was not sufficiently powered for second-
ary outcomes; nevertheless, the incidence of pregnancy, 
or fetal or neonatal complications, were similar in both 
groups. The authors chose aspirin at a dose of 150 mg, on the 
basis of a previously justified dose-dependent therapeutic 
benefit. In conclusion, 150 mg of aspirin given at bedtime 
at 11 to 14 weeks of gestation, until 36 weeks, significantly 
lowered the incidence of developing preterm PE, compared 
to placebo, providing a basis to unify recommendations on 
aspirin commencement. It is worth mentioning that, in this 
study, aspirin did not lower the risk of term PE. 
Based on the conducted studies and histopathological 
observations, it seems justified to initiate treatment before 
16 weeks of gestation as placental implantation and trans-
formation of the maternal spiral arteries are completed be-
tween 16 and 20 weeks of gestation. Thus, it seems that the 
beneficial effect of acetylsalicylic acid is the consequence 
of improved spiral artery transfer [21]. This hypothesis is 
based on two factors: i) low doses of acetylsalicylic acid are 
most effective where early-pregnancy PE prevention is con-
cerned, which is mostly connected with impaired placental 
implantation [26], and ii) abnormal blood flow in maternal 
arteries — already observed at 12 weeks of gestation, in 
women who will later develop PE — significantly improves 
between the first and the second trimester in patients re-
ceiving  acetylsalicylic acid. 
SUMMARY
Preeclampsia remains one of the most serious complica-
tions in pregnancy. Hopefully, in the near future, patients 
attending their first visit (between 12–14 weeks of gestation) 
will be offered screening tests for both PE and genetic abnor-
malities. The current state of knowledge suggests that only 
pre-selected high-risk patients should receive preventive 
low-doses of acetylsalicylic acid. Resistance to acetylsalicylic 
acid remains an area of debate. As many as 30% of preg-
nant women are suspected to be aspirin-resistant. For this 
reason, in centres such as King’s College Hospital, a dosage 
of 150 mg of acetylsalicylic acid at bedtime is used, which 
is a compromise between the dose being effectively thera-
peutic and the risk of possible adverse effects. The belief 
that PE is a condition limited to pregnancy — with the risk 
of termination after placenta removal — is no longer held 
true. Women with a history of PE have an increased risk of 
ischemic heart disease, stroke, cerebrovascular disease, pe-
ripheral arterial disease, cardiovascular mortality and death 
from stroke, chronic hypertension, end-stage renal disease, 
and metabolic disorders. Aspirin is a well-known preventive 
agent diminishing the risk of many of these conditions. Fu-
ture research could be focussed on post-pregnancy aspirin 
use. At the same time, it is important to emphasize that 
screening for PE and pharmacological prophylaxis using 
acetylsalicylic acid requires further, multi-centre randomized 
trials in order to implement both screening tests and preven-
tive measures into daily clinical practice.
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